EMF biological effects
Share

Sphenopalatine ganglion pulsed radiofrequency treatment in 30 patients suffering from chronic face and head pain.

Erin Bayer, Gabor B Racz, Day Miles, James Heavner

PAPERpubmedPain practice : the official journal of World Institute of Pain2005cohortEffect: benefitEvidence: Low

Abstract

This study evaluated the efficacy of sphenopalatine ganglion pulsed radiofrequency (SPG-PRF) treatment in patients suffering from chronic head and face pain. Thirty patients were observed from 4 to 52 months after PRF treatment. The primary efficacy measures were the reduction in oral medication use, including opioids, time-to-next-treatment modality for presenting symptoms, duration of pain relief, and the presence of residual symptoms. Secondary objectives included the evaluation of adverse effects and complications. All data were derived from patient charts, phone conversations, and clinical follow-up visits. Fourteen percent of respondents reported no pain relief, 21% had complete pain relief, and 65% of the patients reported mild to moderate pain relief from SPG-PRF treatment. Sixty-five percent of the respondents reported mild to moderate reduction in oral opioids. None of the patients developed significant infection, bleeding, hematoma formation, dysesthesia, or numbness of palate, maxilla, or posterior pharynx. A large-scale study of SPG-PRF for the treatment of face and head pain has not been previously reported. Our results suggest that a prospective, randomized, controlled trial study to confirm efficacy and safety of this novel treatment for chronic head and face pain is justified.

AI evidence extraction

At a glance
Study type
cohort
Effect direction
benefit
Population
patients with chronic head and face pain
Sample size
30
Exposure
medical pulsed radiofrequency treatment (sphenopalatine ganglion PRF) · follow-up 4 to 52 months after PRF treatment
Evidence strength
Low
Confidence: 74% · Peer-reviewed: yes

Main findings

Among 30 patients followed 4 to 52 months after sphenopalatine ganglion pulsed radiofrequency treatment, 14% reported no pain relief, 21% complete pain relief, and 65% mild to moderate pain relief. Sixty-five percent reported mild to moderate reduction in oral opioids, and no significant complications (infection, bleeding, hematoma, dysesthesia, or numbness) were reported.

Outcomes measured

  • pain relief (none/complete/mild-moderate)
  • reduction in oral medication use (including opioids)
  • time-to-next-treatment modality
  • duration of pain relief
  • residual symptoms
  • adverse effects/complications (infection
  • bleeding
  • hematoma
  • dysesthesia
  • numbness)

Limitations

  • observational follow-up based on charts/phone/follow-up visits (no randomized control described)
  • frequency/SAR and detailed exposure parameters not reported
  • follow-up duration varied (4 to 52 months)
View raw extracted JSON
{
  "study_type": "cohort",
  "exposure": {
    "band": null,
    "source": "medical pulsed radiofrequency treatment (sphenopalatine ganglion PRF)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "follow-up 4 to 52 months after PRF treatment"
  },
  "population": "patients with chronic head and face pain",
  "sample_size": 30,
  "outcomes": [
    "pain relief (none/complete/mild-moderate)",
    "reduction in oral medication use (including opioids)",
    "time-to-next-treatment modality",
    "duration of pain relief",
    "residual symptoms",
    "adverse effects/complications (infection, bleeding, hematoma, dysesthesia, numbness)"
  ],
  "main_findings": "Among 30 patients followed 4 to 52 months after sphenopalatine ganglion pulsed radiofrequency treatment, 14% reported no pain relief, 21% complete pain relief, and 65% mild to moderate pain relief. Sixty-five percent reported mild to moderate reduction in oral opioids, and no significant complications (infection, bleeding, hematoma, dysesthesia, or numbness) were reported.",
  "effect_direction": "benefit",
  "limitations": [
    "observational follow-up based on charts/phone/follow-up visits (no randomized control described)",
    "frequency/SAR and detailed exposure parameters not reported",
    "follow-up duration varied (4 to 52 months)"
  ],
  "evidence_strength": "low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "sphenopalatine ganglion",
    "pulsed radiofrequency",
    "chronic pain",
    "head pain",
    "face pain",
    "opioid reduction",
    "adverse effects"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 3555

Sphenopalatine ganglion pulsed radiofrequency treatment in 30 patients suffering from chronic face and head pain. · Non-native EMF